Ardelyx

Ardelyx, Inc. is a biopharmaceutical company. engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ardelyx reports strong Q4 earnings, poised for product expansion

Ardelyx's Q4 performance reflects revenue growth, improved financial efficiency, and progress towards expanding its product portfolio.
While facing challenges such as regulatory processes and market competition, Ardelyx's strengths lie in successful product launches and a proactive commercial strategy.
Opportunities for Ardelyx include leveraging positive feedback for XPHOZAH, raising additional funds for growth, and diversifying revenue through new product launches.

Ardelyx reports sales growth, readies XPHOZAH launch amid challenges

Ardelyx showed strong sales growth for IBSRELA and is poised for the XPHOZAH launch
Financially, the company raised significant funds and maintains a healthy cash position
Challenges include managing expenses and improving profitability amidst losses
Opportunities lie in upcoming product launches and optimizing financial operations

Ardelyx reports strong Q2 performance amidst legislative challenges and growth opportunities

Ardelyx's Q2 performance reflects growth in IBSRELA sales and overall revenue, despite incurring a net loss.
The company faces challenges from pending legislation and financial burdens related to XPHOZAH launch preparation.
Opportunities lie in the potential of XPHOZAH launch, market reception of IBSRELA, and addressing legislative impacts.

Ardelyx reports strong Q3 earnings, poised for successful XPHOZAH launch

Ardelyx's Q3 performance reflects financial strength and positive market reception for IBSRELA.
Challenges in pricing strategy and market competition require strategic planning for XPHOZAH's launch.
Opportunities lie in leveraging financial stability, physician interest, and promotional activities for XPHOZAH success.
The company's commitment to patient access and learnings from IBSRELA will drive future growth and market penetration.

Ardelyx reports strong revenue growth driven by IBSRELA success

Ardelyx is strategically investing in growth, focusing on sustaining momentum for its products. The company is well-resourced and optimistic about the future performance of IBSRELA and XPHOZAH. Despite challenges in operating expenses, Ardelyx remains committed to its commercialization efforts.

Ardelyx reports robust Q1 performance driven by XPHOZAH success

Ardelyx's Q1 2024 earnings call showcased strong revenue growth, particularly driven by XPHOZAH and IBSRELA. The company's cash position remains healthy, and there is a clear focus on expanding market reach and driving adoption of key therapies.

Ardelyx reports robust Q2 earnings, focuses on patient access advocacy

Ardelyx's Q2 2024 performance reflects strong revenue growth driven by IBSRELA and XPHOZAH, with a focus on shareholder value and patient access advocacy. While facing challenges in legal battles and expense management, the company is poised to capitalize on opportunities through sales force expansion and market differentiation strategies.

Ardelyx (ARDX) reports robust Q3 earnings, navigates Medicare coverage challenges

Ardelyx's Q3 earnings call highlighted strong financial performance, success of key medications, and strategies to address Medicare coverage challenges. The company's focus on patient access, commitment to therapy availability, and positive market impact showcase its growth potential and resilience in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

WALTHAM, Mass., May 17, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting the efficacy and safety of IBSRELA will be presented in three posters at the 2022 Digestive Disease Week Conference (DDW 2022) to be held May 21-24, 2022, in San Diego, California and virtually.

Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022

Ardelyx, Inc. (NASDAQ:ARDX ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Justin Renz - Chief Financial Officer Mike Raab - President and Chief Executive Officer Susan Rodriguez - Chief Commercial Officer Robert Blanks - Chief Regulatory Affairs and Quality Assurance Officer Conference Call Participants Chris Howerton - Jeffrey Carly Kenselaar - Citi Joseph Thome - Cowen and Company Sam Brandeis - Wedbush Matthew Kaplan - Ladenburg Thalmann Operator Good afternoon and welcome to Ardelyx's First Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode.

Ardelyx, Inc. (ARDX) CEO Mike Raab on Q1 2022 Results - Earnings Call Transcript

Conference Call Scheduled for 4:30 PM Eastern Time Today WALTHAM, Mass. , May 5, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today provided a business update and reported financial results for the first quarter ended March 31, 2022.

Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights

Positive interim response for appeal of XPHOZAH received for CKD-PH patients; Advisory Committee could possibly turn things around for possible FDA approval. IBSRELA launched commercially in the United States on April 4, 2022; IBS-C market proven with revenues generated by sales of Linzess and Trulance.

Ardelyx: Speculative Biotech With Minimal Downside Risk For Time Being

— Conference Call scheduled for 4:30 PM Eastern Time WALTHAM, Mass. , April 28, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it will hold a conference call on Thursday May 5, at 4:30 pm Eastern Time to review first quarter 2022 financial results and provide a business overview.

Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022

Ardelyx Inc (NASDAQ: ARDX) shares are trading higher by 29.32% at $0.97 after the company reported it received an interim response from the OND, CDER and FDA for the company's second level of appeal of the Complete Response Letter for XPHOZAH. Ardelyx says the OND intends to direct the.

Why Ardelyx Shares Are Rising

The FDA's Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), has provided an interim response to Ardelyx Inc's (NASDAQ: ARDX) second level of appeal of the Complete Response Letter (CRL) for Xphozah.  Ardelyx is seeking approval for Xphozah.

FDA Plans To Convene AdComm For Ardelyx's Tenapanor For CKD Patients On Dialysis

Cenntro Inc

ERYTech Pharma SA Sponsored ADR

Here's what you need to know about trading penny stocks on April 25th The post Best Penny Stocks to Buy as April Ends? 3 to Watch Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy as April Ends? 3 to Watch Today

- Ardelyx welcomes the opportunity for the company, patients, and practicing nephrologists to speak to clinically meaningful results in treating hyperphosphatemia - WALTHAM, Mass. , April 25, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA), has provided an interim response to Ardelyx's second level of appeal of the Complete Response Letter (CRL) received on July 28, 2021, for XPHOZAH.

Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)

Ardelyx Inc (NASDAQ: ARDX) has amended its license agreement, initially executed in 2017, granting Kyowa Kirin exclusive rights to develop and commercialize Ardelyx's tenapanor for cardiorenal diseases, including hyperphosphatemia, in Japan. Under the agreement, considering.

Kyowa Kirin To Cut Royalty Payment Rate To Ardelyx For Tenapanor In Cardiorenal Disorders

WALTHAM, Mass. , April 11, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it has reached an agreement with its Japanese collaboration partner, Kyowa Kirin Co. Ltd.

Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor

Four posters support the important role that XPHOZAH, with its novel phosphate blocking mechanism, could potentially play in the treatment of hyperphosphatemia XPHOZAH alone or in combination with binders, increased the proportion of patients able to achieve target phosphorus levels Patients reported improved experience with phosphate management routine during OPTIMIZE study, compared to previous phosphate lowering therapies Responder analysis from PHREEDOM demonstrates 77% of patients experienced phosphate lowering with XPHOZAH, with 41% of responders achieving a > 2 mg/dL decrease WALTHAM, Mass. , April 7, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced multiple presentations covering additional positive clinical observations of XPHOZAH at the National Kidney Foundation 2022 Spring Clinical Meetings (NKF SCM2022), which is taking place in Boston, MA from April 6-10, 2022.

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings

Ocugen, Inc.

Tonix Pharmaceuticals Hld

Can these biotech penny stocks continue to make gains? The post Hot Biotech Penny Stocks to Watch During the First Full Week of April  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Penny Stocks to Watch During the First Full Week of April

IBSRELA ® (tenapanor) is the First and Only NHE3 Inhibitor FDA Approved for the Treatment of IBS-C in Adults First Novel Mechanism Therapy to Treat IBS-C in a Decade Product Now Available WALTHAM, Mass. , April 4, 2022 /PRNewswire/ --  Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced the launch of IBSRELA, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults

Borqs Technologies

Castor Maritime Inc

Which penny stocks are you watching right now? The post Good Penny Stocks To Watch During the Bear Market Right Now?

Good Penny Stocks To Watch During the Bear Market Right Now?

Globalstar

Harmony Gold Mining Co Ltd

Which penny stocks are on your March 2022 watchlist as volatility continues? The post Are These Penny Stocks on Your Buy List Right Now?

Are These Penny Stocks on Your Buy List Right Now? 3 to Watch

WALTHAM, Mass., March 2, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a GI/Microbiome panel discussion at the Cowen 42nd Annual Health Care Conference, which is taking place virtually on Wednesday March 9, 2022, at 10:30 AM Eastern Time.

Ardelyx to Participate at the Cowen 42nd Annual Health Care Conference

Ardelyx Inc (NASDAQ: ARDX) shares are trading higher after Jefferies upgraded shares to Buy from Hold and raised the price target on the stock to $5 from $1. Analyst Chris Howerton thinks Ardelyx "stands out" given that the Company has an approved IBS-C product, Isbrela, that.

Jefferies Raises Price Target On This Small-Cap 'Stand Out' Biotech Stock

Farmmi

Toughbuilt Industries Inc

VEON

Penny stocks to buy for under $1. The post Penny Stocks Under $1 To Watch In March 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks Under $1 To Watch In March 2022

Ardelyx, Inc. (ARDX) CEO Mike Raab on Q4 2021 Results - Earnings Call Transcript

Ardelyx (ARDX) delivered earnings and revenue surprises of -24% and 48.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Reports Q4 Loss, Misses Revenue Estimates

WALTHAM, Mass., Feb. 28, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business events and financial results for the fourth quarter and full year ended December 31, 2021.

Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

WALTHAM, Mass. , Feb. 24, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it has entered into a debt financing agreement with investment affiliates managed by SLR Capital Partners ("SLR").

Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital Partners

WALTHAM, Mass., Feb. 22, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it will hold a conference call on Monday February 28, at 4:30 pm Eastern Time to discuss fourth quarter and year-end 2021 financial results and provide a corporate update.

Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

Normally, the title would mean something negative, but I mean it quite literally.

News for Ardelyx Stock (ARDX)